CN101095768B - 一种治疗中老年原发性高血压的中药胶囊 - Google Patents
一种治疗中老年原发性高血压的中药胶囊 Download PDFInfo
- Publication number
- CN101095768B CN101095768B CN200710015375A CN200710015375A CN101095768B CN 101095768 B CN101095768 B CN 101095768B CN 200710015375 A CN200710015375 A CN 200710015375A CN 200710015375 A CN200710015375 A CN 200710015375A CN 101095768 B CN101095768 B CN 101095768B
- Authority
- CN
- China
- Prior art keywords
- semen
- radix
- acori graminei
- fructus
- rhizoma acori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims description 33
- 208000007530 Essential hypertension Diseases 0.000 title claims description 20
- 239000000463 material Substances 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 14
- 241000405414 Rehmannia Species 0.000 abstract 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 1
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000804384 Cynomorium songaricum Species 0.000 abstract 1
- 241000201320 Ligustrum japonicum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241001533104 Tribulus terrestris Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 23
- 210000003734 kidney Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 11
- 230000035487 diastolic blood pressure Effects 0.000 description 10
- 208000002173 dizziness Diseases 0.000 description 10
- 208000013403 hyperactivity Diseases 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010022437 insomnia Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- 240000005373 Panax quinquefolius Species 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 241000201295 Euphrasia Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010059013 Nocturnal emission Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- -1 Herba Apocyni veneti Chemical compound 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002877 dihydralazine Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- HIUVKVDQFXDZHU-UHFFFAOYSA-N guanoxan Chemical compound C1=CC=C2OC(CNC(=N)N)COC2=C1 HIUVKVDQFXDZHU-UHFFFAOYSA-N 0.000 description 1
- 229960000760 guanoxan Drugs 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗中老年原发性高血压的中药胶囊,其特征在于它是由下列重量百分比的药物原料组成:生地、熟地各占9.5-11.0%,何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各占4.0-6.0%,车前子、决明子各占6.5-7.0%,菊花、远志(炙)、石菖蒲各占2.6-4.0%,细辛占0.2-2.0%。该治疗中老年原发性高血压的中药胶囊,治愈率较高、治疗时间短、服用方便、治疗费用低、无毒副作用,适用于各种类型的中老年原发性高血压患者。
Description
技术领域
本发明属于一种治疗高血压的药物,尤其是一种治疗中老年原发性高血压的中药胶囊。
技术背景
原发性高血压病是高血压病中的一种,是相对于继发性高血压疾病而言的,发病率较高,尤其是中老年人,发病率可达10%左右,病情具有整体关联性和逐步发展性,多诱发脑、中枢、心、肾靶器官和络脉组织产生不同程度的生理功能病变,主要以血流供求关系异常导致心脑血管疾病而危及生命。心脏是高血压累及的主要靶器官之一,主要引起左心室肥厚,左心室肥厚又使左心室舒张和收缩功能减退,最终导致心力衰竭;在对肾的影响方面,主要导致肾功能衰竭,且发生率为42%,仅次于心脏并发症,约10%死于肾功能衰竭。临床通常的表现症状有头痛,多发生在后脑部,还伴有头晕、头胀、颈部扳住感、耳鸣、眼花、健忘、失眠、烦闷、乏力、四肢麻木、心悸等。也是造成偏瘫、脑梗塞、脑出血的重要原因,临床上因高血压病发生致残、致死的病例屡见不鲜,故常称谓“隐形杀手”。对于中老年原发性高血压的治疗,临床上多以采用化学药物治疗为主,具有显效快、较好的控制血压水平的优点,主要有以下五类:利尿降压药、β1受体阻滞剂、钙离子拮抗剂、α1受体阻滞剂、血管紧张素转换酶抑制剂等。化学药物虽然作用迅速,但降压过程中血压波动大、副作用也大,可明显影响水、电解质、血脂、血糖等的代谢,直接损伤心、脑、肾等器官,同时这些化学药物对高血脂、高血粘度、血管硬化、靶器官的损伤等无改善作用,所以西药只能是服了降,降了又升,反反复复,需终身服药。也有的采用中西药复方降压药物,如新降片含有利血平双肼苯哒嗪、珍珠母、车前子等成分;珍珠降压片含有可乐宁、双氢克尿塞、野菊花、珍珠层、槐米等;复方罗布麻片含有胍己啶或胍生、罗布麻、双氢克尿塞、肼苯哒等,这些药中的中药成分较少,仅起辅助作用,降压作用仍靠西药成分。中医治疗中老年原发性高血压病强调辨证论治,整体观念,临床上一般分为肝火亢盛、阴虚阳亢、痰湿壅盛和阴阳两虚四种证型,依据疾病的中医证型,合理处方用药,可明显提高治疗效果,目前治疗此类高血压病的中药有:复方菊花汤,包括菊花、桑叶、枸杞、生石决明组成;六味地黄丸,包括熟地黄、泽泻、茯苓、山药、钩藤、夏枯草、牡丹皮、石决明、山茱萸组成;杞菊地黄丸,包括枸杞、熟地黄、山药、牡丹皮、丹参、生龙骨、生牡蛎、杜仲、川牛膝、龟板、甘草组成。有些中药汤剂,仅对某一种证型的高血压有作用,不能治疗各种类型的原发性高血压,如龙胆泻肝汤,包括龙胆草、栀子、黄芩、生地黄、钩藤、生石决明、川牛膝、杜仲、夜交藤、甘草组成,仅对阴虚阳亢型有效;又如半夏白术天麻汤,包括半夏、白术、天麻、远志、甘草组成,仅治疗痰湿壅盛型有效,不能治疗其他类型的高血压。此类中药副作用较轻,也有一定疗效,但有效率较低,复发率较高。
发明内容
本发明的目的在于提供一种不仅对中老年原发性高血压治疗无毒副作用,而且治愈率较高、复发率较低、可适用于治疗各种类型的中老年原发性高血压、而且无不良反应的治疗中老年原发性高血压的中药胶囊。
为达到以上目的,本发明所采取的技术方案是:该一种治疗中老年原发性高血压的中药胶囊,由清肝泻火药物、清热凉血药物、滋阴补血药物、活血化瘀药物、益阴助阳药物、芳香开窍药物、解表止痛药物和安神益智药物,按合理配比制成,其特征在于它是由下列重量百分比的药物原料组成:生地、熟地各占9.5-11.0%,何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各占4.0-6.0%,车前子、决明子各占6.5-7.0%,菊花、远志(炙)、石菖蒲各占2.6-4.0%,细辛占0.2-2.0%。本发明还通过如下措施实施:所述的石菖蒲为泡制石菖蒲细粉,其泡制步骤是:先把石菖蒲粉碎成粉状,加入3-5倍的无水乙醇,浸泡5-8天,滤过,滤液用常规蒸馏法回收乙醇,即得石菖蒲细粉,备用;其余的生地、熟地、何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子、车前子、决明子、菊花、远志(炙)、细辛加水浸泡12小时,煮沸三次,第一次2小时,第二次1小时,第三次半小时,合并煎液,滤过,滤液减压浓缩后,加入上述石菖蒲细粉,混匀,低温减压干燥,粉碎,过40目筛,混匀,装入胶囊,每粒0.4克,即为该治疗中老年原发性高血压的中药胶囊,包装备服用。
服用方法:口服,一日2-3次,每次2粒。服药期间,忌食辛辣、油腻食物,如辣椒、烧酒、过多的动物脂肪。孕妇慎用。
本发明的优点在于:与目前临床应用的治疗中老年原发性高血压的中成药物相比,治愈率较高、治疗时间短、服用方便、治疗费用低、无毒副作用,适用于各种类型的中老年原发性高血压患者。
临床疗效观察实验:
一、临床资料
采用该中药胶囊共治疗180个病例,均来自门诊病例,其中,按性别分:男100例,女80例;按年龄分:30-59岁68例,60岁以上112例;按病程分:最短的1周,最长的30年,平均12年;按病期分:急性期42例,慢性期138例;按辩证分型:肝火亢盛型62例、阴虚阳亢型58例、痰湿壅盛型20例、阴阳两虚型40例。血压最高者,收缩压210mmHg,舒张压130mmHg;血压最低者,收缩压140mmHg,舒张压95mmHg。
二、诊断标准
依据1999年WHO有关高血压的定义和诊断标准,诊断标准为:
1.诊断依据:
轻者:收缩压140-159mmHg,舒张压90-99mmHg。
较重者:收缩压160-179mmHg,舒张压100-109mmHg;
重者:收缩压≥180mmHg,舒张压≥110mmHg。
2.辩证分型
根据1993年卫生部《中药新药临床研究指导原则》关于“所确定的辩证标准”,结合临床实际,共分为4个证型:
肝火亢盛证型:症状为眩晕头痛、面红目赤、急躁易怒、口干口苦、便秘溲赤、舌红苔黄、脉眩;
阴虚阳亢证型:证状为眩晕、头痛、腰膝酸软、耳鸣健忘、五心烦热、心悸失眠、舌苔红、苔薄白或少苔、脉弦细而数;
痰湿壅盛证型:证状为眩晕头痛、头痛如裹、胸闷腹胀、心悸失眠、口淡食少、呕吐痰延、舌苔白腻、脉滑;
阴阳两虚证型:证状为眩晕头痛、耳鸣如蝉、心悸气短、腰酸腿软、夜尿频多、失眠多梦、畏寒肢凉、舌淡或红、苔白脉沉细或细数等。
三、治疗结果
疗效标准
治愈:血压恢复到正常标准:收缩压等于或低于140mmHg,同时舒张压等于或低于90mmHg。靶器官损伤肥大消失,眼底检查正常,化验检查正常。
显效:舒张压降至正常范围,且下降幅度≥9.8mmHg,或舒张压虽未降到正常,但下降幅度≥14.0mmHg。
好转:舒张压下降4.9-9.8mmHg,并降至正常范围;或舒张压虽未降至正常水平,但下降9.8-14.0mmHg,或收缩压下降幅度≥30.0mmHg。
无效:为达到上述好转标准。
四、结果分析
1.药理分析:
该治疗中老年原发性高血压的中药胶囊,共有19味中药组成,各药物原料的药理为:生地、熟地:具有滋补阴血、益精髓、补精益髓的作用,多用于腰酸腿软、头昏眼花、耳鸣耳聋、滋阴补肾;何首乌:具有补肝益肾、止心痛、益气血、益精髓、降血脂、抗硬化、强化活血化淤、强筋骨、增强免疫力的作用;桑椹子:归心肝肾经,主要补肝肾、益血名目;女贞子:具有养肝肾之阴、滋肾养肝、补气益血、健肾培脾的作用;沙苑子:具有固精气、补肝肾、明双目、固精明目的作用;蒺藜:归肝经、具有平肝解郁、活血祛风、明目、止痒的作用;锁阳:用于补肾润肠通便、益阳固精、强筋壮骨、肾虚阳萎、腰膝无力、遗精滑泄、尿血、肠燥便秘;怀牛膝:具有活血化淤、补益肝肾、延长凝血时间和短暂的降血压作用;菟丝子:含树脂甙,糖类,具有补肝肾、养精髓、壮阳明目、免疫降血压的作用;莱菔子:能清除胃肠胀满和胃降逆,在胃肠中有气化作用,可顺气开郁、消食导滞、降气消痰;炒白术:具有补脾益气、健脾燥湿、保护肝脏、防止肝糖元减少的作用;枸杞子:具有补肝益阴、益精补血、明目、大补肝肾阴的作用;车前子:归肝、肾、肺、小肠、膀胱经,具有清热利尿、渗湿止泻、清肝明目、清肺化痰的功效;决明子:归肝肾、大肠经,不仅能明目,还能调节血脂、降血压的作用;菊花:具有疏散风热、清肝平肝、疏肝祛风清热、清肝明目、降血压的作用;远志(炙):能安神益智、去痰、解郁、交通心肾,主治惊悸、健忘、失眠、咳嗽多痰、痛疽疮肿、郁症,入心、肝、脾经;石菖蒲:归心、胃经,具有化湿开胃、开窍豁痰、镇静安神、降血压、解痉、抗菌消炎、解毒、理气、活血的功效;细辛:入心、肝、肾,具有散风开窍,风寒湿痹,有镇痛作用。其中生地、菊花、决明子、车前子四味中药,主要治疗肝火亢盛型高血压;熟地、何首乌、桑椹子、女贞子、沙苑子五味中药主要治疗阴虚阳亢型高血压;莱菔子、怀牛膝、远志(炙)、炒白术四味中药,主治痰湿壅盛型高血压;锁阳、菟丝子、枸杞子与熟地、何首乌、桑椹子、女贞子、沙苑子合奏阴阳双补之功效,主要用于阴阳两虚型高血压;石菖蒲、细辛,辅助以上诸药增强疗效。
2.疗效结果分析
通过对以上180例患者治疗,服用6个月,经过按疗效标准检查,确定共治愈128例,治愈率为71.1%;显效18例,显效率为10%;好转28例,好转率为15.6%;无效6例,无效率为3.3%;总有效174例,总有效率为96.7%。
经追踪观察2年,治愈的128例中,复发2例,占3.1%,仍服用该治疗高血压的中药胶囊治愈;治愈例中,疗程最短的7天,最长的1年。临床观察无任何毒副作用及不良反应。
具体实施方式
实施例1
生产1000g该中药胶囊,称取:生地、熟地各100g,何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各50g,车前子、决明子各67g,菊花、远志(炙)、石菖蒲各33g,细辛17g。将称取的石菖蒲粉碎,加入4倍的无水乙醇浸泡7天,滤过,滤液用常规蒸馏法回收乙醇,制得石菖蒲细粉,备用;其余的18味加水浸泡12小时,煮沸三次,第一次2小时,第二次1小时,第三次半小时,合并煎液,滤过,滤液减压浓缩后,加入上述石菖蒲细粉,混匀,低温减压干燥,过40目筛,混匀,装入胶囊,每粒胶囊装0.4克。
采用本配比,共治疗肝火亢盛型20例、阴阳两虚型30例、阴虚阳亢型20例,疾湿壅盛型10例,共治愈62例,治愈率77.5%,显效12例,显效率15.0%,好转6例,好转率7.5%。
典型病例
谷志寰,男,54岁,莱芜市莱城区张家洼镇山子后村人。2005年5月,后脑勺头痛,头晕、耳鸣、眼花、健忘、失眠。来门诊就诊,经检查,血压170/110mmHg,其他未见异常,确诊为原发性高血压症,服用该中药胶囊后,10天见效,一个月后基本恢复正常,巩固治疗一个月后治愈,至今未见复发。
实施例2
生产1000g该中药胶囊,称取:生地、熟地各95g,何首乌、桑椹子、女贞子、沙苑子、蒺藤、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各51g,车前子、决明子各70g,菊花、远志(炙)、石菖蒲各34g,细辛7g。生产工艺同实施例1。采用本配比,主要治疗痰湿壅盛型20例,共治愈14例,治愈率为70.0%,显效4例,显效率为20.0%,无效2例,无效率为10.0%,总有效率93.3.%。
典型病例
郑永东,男,48岁,莱芜市莱城区梁坡村。2005年3月,头晕、头胀、耳鸣、眼花、健忘、失眠。来门诊就诊,经检查,血压170/100mmHg,其他未见异常,确诊为原发性高血压症,服用该中药胶囊后,10天见效,一个月后明显好转,治疗二个月后治愈正常,2年未复发。
实施例3
生产1000g该中药胶囊,称取:生地、熟地各110g,何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各52g,车前子、决明子各65g,菊花、远志(炙)、石菖蒲各27g,细辛7g。生产工艺同实施例1。采用此配方治疗肝火亢盛型38例,共治愈30例,治愈率78.9%,显效5例,显效率13.2%,3例无效。
典型病例
汪小玲,女,67岁,莱芜市莱城区李家泉村。。2005年11月,感到头晕,眼前常发黑,耳鸣、眼花、健忘、失眠。来门诊就诊,经检查,血压170/110mmHg,其他未见异常,确诊为原发性高血压症,服用该中药胶囊后,10天见效,2周后明显好转,治疗一个月后恢复正常,1年未复发。
Claims (2)
1.一种治疗中老年原发性高血压的中药胶囊,其特征在于它是由下列重量百分比的药物原料制成:生地、熟地各占9.5-11.0%,何首乌、桑椹子、女贞子、沙苑子、蒺藜、锁阳、怀牛膝、菟丝子、莱菔子、炒白术、枸杞子各占4.0-6.0%,车前子、决明子各占6.5-7.0%,菊花、炙远志、石菖蒲各占2.6-4.0%,细辛占0.2-2.0%。
2.根据权利要求1所述的治疗中老年原发性高血压的中药胶囊,其特征在于所述的石菖蒲为泡制石菖蒲细粉,其泡制步骤是:先把石菖蒲粉碎成粉状,加入3-5倍的无水乙醇,浸泡5-8天,滤过,滤液用常规蒸馏法回收乙醇,即制得石菖蒲细粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710015375A CN101095768B (zh) | 2007-07-16 | 2007-07-16 | 一种治疗中老年原发性高血压的中药胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710015375A CN101095768B (zh) | 2007-07-16 | 2007-07-16 | 一种治疗中老年原发性高血压的中药胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101095768A CN101095768A (zh) | 2008-01-02 |
CN101095768B true CN101095768B (zh) | 2010-05-19 |
Family
ID=39009989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710015375A Expired - Fee Related CN101095768B (zh) | 2007-07-16 | 2007-07-16 | 一种治疗中老年原发性高血压的中药胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101095768B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698124B (zh) * | 2012-01-17 | 2013-11-06 | 李付德 | 一种治疗阳虚双相型高压高、低压高高血压的中药组合物 |
CN103432285B (zh) * | 2013-07-24 | 2015-10-07 | 江苏苏南药业实业有限公司 | 一种治疗眩晕的中药颗粒及其制备方法 |
CN104547643A (zh) * | 2015-01-08 | 2015-04-29 | 季一艮 | 一种用于治疗高血压的中药组合物 |
CN105726573A (zh) * | 2016-05-09 | 2016-07-06 | 林荣波 | 一种治疗肝阳上亢所致高血压的中药组合物 |
CN113694125A (zh) * | 2021-09-06 | 2021-11-26 | 上海中医药大学附属龙华医院 | 一种专用于抗动脉粥样硬化的益肾口服液及制备方法 |
CN115475204A (zh) * | 2022-11-08 | 2022-12-16 | 上海中医药大学附属岳阳中西医结合医院 | 一种治疗精血虚衰疾病的中药组合物及其应用 |
CN117899158A (zh) * | 2023-12-13 | 2024-04-19 | 贵州中医药大学第一附属医院 | 一种治疗阴虚阳亢型高血压的药物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249939A (zh) * | 1998-10-05 | 2000-04-12 | 王平 | 高脂血症丸 |
-
2007
- 2007-07-16 CN CN200710015375A patent/CN101095768B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249939A (zh) * | 1998-10-05 | 2000-04-12 | 王平 | 高脂血症丸 |
Also Published As
Publication number | Publication date |
---|---|
CN101095768A (zh) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103071128B (zh) | 一种治疗痛经的外用贴膏 | |
CN103041282A (zh) | 治疗脾肾两虚的中药及其制备方法 | |
CN101284105A (zh) | 用于治疗心脑血管病的溶栓降脂丹 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN103393879A (zh) | 一种治疗肝肾阴虚的中药组合物 | |
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN104127699A (zh) | 益元养生制剂及其制备方法 | |
CN106421649A (zh) | 一种治疗脑中风的中药组合物及其制备方法 | |
CN104940740A (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 | |
CN102366468A (zh) | 一种治疗白癜风的中药 | |
CN102210839B (zh) | 一种治疗冠心病的中药胶囊 | |
CN104225166A (zh) | 一种治疗闭经的中药组合物及其制备方法 | |
CN101496892B (zh) | 一种治疗心脑血管疾病的口服中成药 | |
CN106421432A (zh) | 一种治疗老年体虚症,延缓衰老的中药 | |
CN102641471B (zh) | 一种治疗胆结石的中药 | |
CN102125645B (zh) | 治疗骨质疏松的中药制剂 | |
CN104815232A (zh) | 一种治疗原发性肺动脉高压的中药制剂及其制备方法 | |
CN103536849A (zh) | 治疗肺栓塞的药物及其制备方法 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN103006980A (zh) | 一种治疗痞满的中药组合物 | |
CN102579818A (zh) | 一种藏药组合物及其制备方法与应用 | |
CN103212044B (zh) | 一种治疗心血管疾病的中药组合物 | |
CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
CN105194355A (zh) | 一种治疗原发性高血压的中药制剂 | |
CN104258351A (zh) | 一种治疗酒精性心肌病的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20100716 |